Q-omics provides the consensus-scored BCL7C profile across patient tissues and cancer cell-line models. BCL7C expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, BCL7C is differentially expressed in 12, with the highest sampling consensus in KICH. Additionally, BCL7C RNA expression shows 19,131 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LIHC, KICH, and THYM as cancer lineages where BCL7C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCL7C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCL7C survival associations across molecular data types. BCL7C RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCL7C RNA expression–survival associations across cancer types. High BCL7C expression shows unfavorable associations in LIHC, ACC, LGG, KICH and SKCM, but favorable associations in OV. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for BCL7C RNA expression.
This table summarizes BCL7C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KICH for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for BCL7C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCL7C shows lower tumor expression in KICH and higher tumor expression in HNSC, LIHC, COAD, LUSC and BRCA. The KICH box plot shows higher BCL7C RNA expression in normal versus tumor tissue (log2 FC = −1.372, t-test p < 0.001).
This table shows molecular features associated with BCL7C in patient tissues and cancer cell lines. In patient samples, BCL7C shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, BCL7C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and CNS.
